Radioiodine treatment for graves' disease: a 10-year Australian cohort study.

Autor: Fanning E; Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia. e.fanning@uq.edu.au.; Faculty of Medicine, the University of Queensland, Brisbane, Queensland, Australia. e.fanning@uq.edu.au., Inder WJ; Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia. warrick.inder@health.qld.gov.au.; Faculty of Medicine, the University of Queensland, Brisbane, Queensland, Australia. warrick.inder@health.qld.gov.au., Mackenzie E; Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.; Nuclear Medicine, Department of Radiology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Jazyk: angličtina
Zdroj: BMC endocrine disorders [BMC Endocr Disord] 2018 Dec 12; Vol. 18 (1), pp. 94. Date of Electronic Publication: 2018 Dec 12.
DOI: 10.1186/s12902-018-0322-7
Abstrakt: Background: Radioactive iodine (I 131 ) is a common definitive treatment for Graves' Disease. Potential complications include worsening, or new development of Graves' eye disease and development of a radiation thyroiditis. The purpose of the present study was to assess outcomes of patients treated with I 131 in an Australian tertiary centre over 10 years.
Methods: Data from 101 consecutive patients treated with I 131 for a diagnosis of Graves' disease between 2005 to 2015 was collected and reviewed retrospectively. Baseline TSH receptor antibody titre, pre-treatment free thyroxine (FT4), technetium scan uptake, initial treatment, duration of treatment, reason for definitive therapy, complications, and time to remission (defined as euthyroidism or hypothyroidism after 12 months) were recorded.
Results: Of the 92 patients with adequate outcome data, 73 (79.3%) patients achieved remission with a single dose of I 131 . Of the remaining 19 patients, 12 had a second dose and became hypothyroid. TSH receptor antibody titre at diagnosis was significantly lower in the group that achieved remission with the first dose compared with those who did not (P = 0.0071). There was no difference in technetium uptake, I 131 dose, duration of therapy or pre-treatment free thyroxine (FT4). I 131 was complicated by development of eye disease in 3 patients and 1 (of 11 with pre-existing eye disease) had worsening eye disease. A clinically apparent flare of hyperthyroidism following I 131 was evident in 8 patients (8.6%).
Conclusion: Radioiodine is an effective therapy for Graves' Disease with few complications. The majority of patients achieve remission with a single dose. Those who require a second dose are more likely to have higher TSH receptor antibody titres at diagnosis. To the best of our knowledge, this is the first study to report outcomes from radioiodine treatment for Graves' disease in an Australian population.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje